ENDRA Life Sciences Announces Strategic Public Offering Deal
Company Announcements

ENDRA Life Sciences Announces Strategic Public Offering Deal

ENDRA Life Sciences (NDRA) just unveiled an update.

ENDRA Life Sciences, Inc. has partnered with Craig-Hallum Capital Group LLC to manage a public offering of over 6 million shares of common stock, warrants, and pre-funded warrants, closing with approximately $8 million in gross proceeds. The offering, completed on June 5, 2024, included common and pre-funded warrants paired with Series A and B warrants, with exercise prices set at $0.22. However, the warrants are subject to stockholder approval and a charter amendment to increase authorized shares. The deal also involves a 90-day lock-up period for company insiders and a cash plus stock compensation to the placement agent, with the company safeguarded against certain legal liabilities.

See more insights into NDRA stock on TipRanks’ Stock Analysis page.

Related Articles
Christine BrownIs NDRA a Buy, Before Earnings?
TheFlyENDRA Life Sciences Inc trading resumes
TheFlyENDRA Life Sciences Inc trading halted, volatility trading pause
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App